Kenneth Allen Myszkowski net worth and biography

Kenneth Myszkowski Biography and Net Worth

Kenneth A. Myszkowski, Chief Financial Officer, joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation, and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.

What is Kenneth Allen Myszkowski's net worth?: The estimated net worth of Kenneth Allen Myszkowski is at least $7.44 million as of January 6th, 2025. Mr. Myszkowski owns 473,433 shares of Arrowhead Pharmaceuticals stock worth more than $7,437,632 as of May 17th. This net worth estimate does not reflect any other investments that Mr. Myszkowski may own. Additionally, Mr. Myszkowski receives an annual salary of $834,340.00 as CFO at Arrowhead Pharmaceuticals. Learn More about Kenneth Allen Myszkowski's net worth.
How old is Kenneth Allen Myszkowski?: Mr. Myszkowski is currently 58 years old. There are 6 older executives and no younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals is Dr. Bruce D. Given M.D., Chief Medical Scientist, who is 70 years old. Learn More on Kenneth Allen Myszkowski's age.
What is Kenneth Allen Myszkowski's salary?: As the CFO of Arrowhead Pharmaceuticals, Inc., Mr. Myszkowski earns $834,340.00 per year. There are 2 executives that earn more than Mr. Myszkowski. The highest earning executive at Arrowhead Pharmaceuticals is Dr. Christopher R. Anzalone Ph.D., CEO, President & Director, who commands a salary of $1,600,000.00 per year. Learn More on Kenneth Allen Myszkowski's salary.
How do I contact Kenneth Allen Myszkowski?: The corporate mailing address for Mr. Myszkowski and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Kenneth Allen Myszkowski's contact information.
Has Kenneth Allen Myszkowski been buying or selling shares of Arrowhead Pharmaceuticals?: Kenneth Allen Myszkowski has not been actively trading shares of Arrowhead Pharmaceuticals during the past quarter. Most recently, Kenneth Allen Myszkowski sold 27,167 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a transaction totalling $538,721.61. Following the completion of the sale, the chief financial officer now directly owns 473,433 shares of the company's stock, valued at $9,388,176.39. Learn More on Kenneth Allen Myszkowski's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Hongbo Lu (Director), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), Victoria Vakiener (Director), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 432,706 shares worth more than $7,229,502.79. The most recent insider tranaction occured on April, 11th when CEO Christopher Richard Anzalone sold 50,800 shares worth more than $583,692.00. Insiders at Arrowhead Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 4/11/2025.

Kenneth Allen Myszkowski Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	Sell	27,167	$19.83	$538,721.61	473,433
3/6/2024	Sell	40,000	$35.19	$1,407,600.00	400,600
1/5/2024	Sell	16,104	$35.27	$567,988.08	440,600
6/27/2023	Sell	15,000	$36.20	$543,000.00	381,704
12/29/2022	Sell	30,625	$40.00	$1,225,000.00	336,704
1/5/2022	Sell	40,000	$61.70	$2,468,000.00
1/12/2021	Sell	13,038	$81.02	$1,056,338.76	445,446
1/6/2021	Sell	30,625	$72.44	$2,218,475.00	486,568
10/20/2020	Sell	29,166	$54.04	$1,576,130.64	456,834
1/21/2020	Sell	40,313	$49.44	$1,993,074.72	424,536
1/6/2020	Sell	20,000	$60.11	$1,202,200.00	403,592
11/1/2019	Sell	37,884	$40.85	$1,547,561.40	351,420
5/21/2019	Sell	27,071	$22.00	$595,562.00	278,536
2/19/2019	Sell	8,000	$18.00	$144,000.00	313,607
1/17/2019	Sell	81,875	$14.55	$1,191,281.25	305,607
1/2/2019	Sell	8,333	$11.98	$99,829.34	395,815
9/6/2018	Sell	45,000	$19.34	$870,300.00	335,815
6/19/2018	Sell	20,000	$14.01	$280,200.00	330,815
5/31/2018	Sell	14,000	$11.00	$154,000.00	312,215
3/27/2018	Sell	20,000	$8.00	$160,000.00	330,815
8/23/2016	Sell	6,900	$8.00	$55,200.00	128,789
8/22/2016	Sell	13,100	$8.00	$104,800.00	128,789
12/30/2015	Sell	23,347	$6.13	$143,117.11	135,000
2/12/2014	Sell	16,000	$18.77	$300,320.00

Kenneth Allen Myszkowski Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $15.71

$15.19

$15.85

50 Day Range

MA: $13.30

$9.99

$15.77

2 Week Range

Now: $15.71

$9.57

$30.41

Volume

1,821,408 shs

Average Volume

1,483,733 shs

Market Capitalization

$2.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Kenneth Myszkowski Biography and Net Worth

What is Kenneth Allen Myszkowski's net worth?

How old is Kenneth Allen Myszkowski?

What is Kenneth Allen Myszkowski's salary?

How do I contact Kenneth Allen Myszkowski?

Has Kenneth Allen Myszkowski been buying or selling shares of Arrowhead Pharmaceuticals?

Who are Arrowhead Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Arrowhead Pharmaceuticals?